SPL026 With or Without SSRIs in Participants With MDD

This open-label trial (n=24) investigates the difference between those who are and aren’t taking antidepressants (SSRIs) who will receive SPL026 (DMT fumarate). As a Phase I study, the main concern is safety and tolerability. With 24 participants, some signal on effectiveness might be detected.

Topic Safety Depression

Compound DMT

Country United Kingdom

Visit trial

Status Not yet recruiting

Results Published

Start date 01 October 2022

End date 01 February 2023

Chance of happening 80%

Design Open

Type Interventional

Generation Second

Participants 24

Sex All

Age 18- 99

Therapy No

Trial Details

The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.

NCT Number NCT05553691

Sponsors & Collaborators

Small Pharma
Small Pharma works on the development of two drugs. Together with Imperial College London they are developing intravenous administration DMT. The other project is a variant on ketamine (SPL801B).

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.